# Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

> **NCT00570700** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 38 (actual)

## Conditions studied

- Hormone-refractory Prostate Cancer
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Prostate Cancer
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00570700
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570700, "Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00570700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*